Visilizumab
As of the edition of 20 October 2026, Visilizumab is an antibody: stopped in 2013; acts on CD3E.
Sources: FDA Orange Book and Purple Book, other approval registers, ClinicalTrials.gov, ChEMBL.
The drug
- Status
- Stopped, 2013
- Kind
- Antibody
- Registered trials
- 14, 6 stopped early
- Disease areas
- Digestive system; Immune system; Blood and lymph; Cancer; Heart and blood vessels
US protection
No US approval on record.
With no US approval on record there are no listed US patents or exclusivities.
This is the US only.
Companies that need a new molecule because of this drug
1 company on route A because of this drug.
Companies on route A for this drug
In the product1 company is on route A because of Visilizumab.
See the 1 company on route A for this drug, with the facts behind eachRequest access. Nothing is shown until you do.
Target
| Gene | Protein | UniProt |
|---|---|---|
| CD3E | T-cell surface glycoprotein CD3 epsilon chain | P07766 |
Registered trials
| Phase | Trials | Completed | Active | Stopped early |
|---|---|---|---|---|
| Phase not stated | 1 | 0 | 0 | 1 |
| Phase 1 | 1 | 1 | 0 | 0 |
| Phase 2 | 7 | 4 | 0 | 2 |
| Phase 3 | 5 | 1 | 0 | 3 |
| All trials | 14 |
Who ran its trials
| Company | Role | Years |
|---|---|---|
| Abbott | Lead sponsor of trials | 2006 to now |
| PDL BioPharma | Lead sponsor of trials | 2006 to now |